Article

Receiving Ruxolitinib Post Transplant Improves Survival Among Patients With Myelofibrosis

Author(s):

A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following an allogeneic hematopoietic cell transplant.

Insight into the long-term safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients with myelofibrosis is suggesting positive implications of ruxolitinib treatment for these patients when given post transplant.

A study abstract presented at the European Hematology Association annual meeting found that, in a real-world setting, ruxolitinib resulted in prolonged survival among patients receiving the treatment following alloHCT, with 2-year overall survival (OS) improving significantly from 13.1% to 100%.

“Our real-world cohort indicates that the use of ruxolitinib has optimized outcomes of alloHCT. Especially after alloHCT, our results suggest a significant benefit of a personalized approach in ruxolitinib administration,” reflected the researchers, who noted that physicians are reluctant to refer patients for alloHCT since the emergence of Janus kinase 2 inhibitors despite efforts to expand alloHCT indications with improved patient stratification. “Given the safety of alloHCT, further studies are needed to guide this personalized approach.”

Throughout the study period, disease-free survival (DFS) was also superior among patients receiving ruxolitinib post-transplant; patients who received the JAK2 inhibitor after their alloHSCT had a 2-year DFS of 75% compared with 14.3% among patients who did not.

The study included 12 patients receiving alloHCT between 2000 and 2020, 7 of whom had primary myelofibrosis and 5 had secondary myelofibrosis. The majority (8 patients) received their transplant from a sibling donor and 4 received their transplant from an unrelated donor. All 12 patients received peripheral blood stem cells graft, either after myeloablative or reduced intensity conditioning regimens.

Among the patients, there was a 2-year treatment-related mortality rate of 34.6%.

“Ruxolitinib was administered in patients transplanted after 2015: before alloHCT in 6/6 patients, and after alloHCT in 4/6 (2 for relapsed disease, 1 for splenomegaly and thrombocytopenia despite involved field radiation therapy, and 1 for moderate chronic GVHD). Patients that received ruxolitinib post-transplant did not suffer from TRM,” explained the researchers.

Acute graft-versus-host disease (GVHD) was reported in 33% of patients and cumulative incidence of moderate chronic GVHD was 58%.

Reference

Sakellari I, Gavriilaki E, Mallouri D, et al. Improved survival in myelofibrosis patients receiving ruxolotinib post allogeneic hematopoietic cell transplantation. Presented at EHA 2021. Abstract EP1256.

Related Videos
Parth Rali, MD
1 KOL is featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
1 KOL is featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo